EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Renovacor's Enterprise Value is $3.07 Mil.
Renovacor's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 was $-31.29 Mil. Therefore, Renovacor's EV-to-FCF for today is -0.10.
The historical rank and industry rank for Renovacor's EV-to-FCF or its related term are showing as below:
RCOR'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.1 Med: 0 Max: 0.9
Current: -0.1
During the past 2 years, the highest EV-to-FCF of Renovacor was 0.90. The lowest was -0.10. And the median was 0.00.
RCOR's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.31
vs RCOR: -0.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Renovacor's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Renovacor's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renovacor's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Renovacor's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Renovacor's EV-to-FCF falls into.
Renovacor's current Enterprise Value is $3.07 Mil.
Renovacor's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renovacor (AMEX:RCOR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Renovacor's share price for today is $3.20.
Renovacor's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Renovacor EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Renovacor's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCOR has been successfully added to your 